# Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia

> **NCT06832371** · — · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)** · enrollment: 73 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia (HoFH)
- Major Adverse Cardiovascular Events (MACE)
- Dyslipidemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06832371
- **Lead sponsor:** Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832371, "Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT06832371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*